KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Michael Paul Kolinsky, Gwenaelle Gravis,Loic Mourey,Josep M. Piulats,Srikala S. Sridhar, Emanuela Romano,William R. Berry,Howard Gurney,Margitta Retz,Leonard Joseph Appleman,Martin Boegemann,Johann S. De Bono, Anthony M. Joshua,Urban Emmenegger,Henry Jacob Conter, Brigitte Laguerre,Helen Wu,Charles Schloss,Christian Heinrich Poehlein,Evan Y. Yu

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 10|浏览13

暂无评分

摘要

103Background: KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to evaluate pembro in combination with other agents in mCRPC. Here we report updated results from cohort B (pembro + docetaxel and pre...

查看译文

关键词

Enzalutamide,Docetaxel,Pembrolizumab,Prednisone,Cohort,Oncology,Medicine,Abiraterone,Castrate-resistant prostate cancer,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要